Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biosimilar medicines in inflammatory bowel disease.
Moum B, Lundin KE. Moum B, et al. Among authors: lundin ke. Tidsskr Nor Laegeforen. 2014 Apr 29;134(8):819-20. doi: 10.4045/tidsskr.14.0192. eCollection 2014 Apr 29. Tidsskr Nor Laegeforen. 2014. PMID: 24780979 Free article. English, Norwegian. No abstract available.
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ, Ystrøm CM, Lundin KEA, Kvien T, Jahnsen J. Jørgensen KK, et al. BioDrugs. 2020 Oct;34(5):681-694. doi: 10.1007/s40259-020-00438-7. BioDrugs. 2020. PMID: 32965617 Free PMC article. Clinical Trial.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK. Goll GL, et al. J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12. J Intern Med. 2019. PMID: 30762274 Free PMC article. Clinical Trial.
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F. Vesterhus M, et al. J Hepatol. 2017 Jun;66(6):1214-1222. doi: 10.1016/j.jhep.2017.01.019. Epub 2017 Feb 2. J Hepatol. 2017. PMID: 28161472
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation.
Jørgensen SF, Trøseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, Holm K, Høivik ML, Rashidi A, Dahl CP, Vesterhus M, Halvorsen B, Mollnes TE, Berge RK, Moum B, Lundin KE, Fevang B, Ueland T, Karlsen TH, Aukrust P, Hov JR. Jørgensen SF, et al. Among authors: lundin ke. Mucosal Immunol. 2016 Nov;9(6):1455-1465. doi: 10.1038/mi.2016.18. Epub 2016 Mar 16. Mucosal Immunol. 2016. PMID: 26982597 Free article.
[Cancer risk in coeliac disease].
Brottveit M, Lundin KE. Brottveit M, et al. Among authors: lundin ke. Tidsskr Nor Laegeforen. 2008 Oct 23;128(20):2312-5. Tidsskr Nor Laegeforen. 2008. PMID: 19096486 Free article. Review. Norwegian.
[J. Frich and colleagues reply].
Frich J, Lundin KE, Os I. Frich J, et al. Among authors: lundin ke. Tidsskr Nor Laegeforen. 2014 Mar 11;134(5):496; discussion 497. doi: 10.4045/tidsskr.14.0202. eCollection 2014 Mar 11. Tidsskr Nor Laegeforen. 2014. PMID: 24621892 Free article. Norwegian. No abstract available.
[Disease mechanisms in coeliac disease].
Sollid LM, Lundin KE. Sollid LM, et al. Among authors: lundin ke. Tidsskr Nor Laegeforen. 2003 Nov 20;123(22):3230-3. Tidsskr Nor Laegeforen. 2003. PMID: 14714017 Free article. Norwegian.
[The grading system--balancing various interests].
Frich J, Lundin KE, Os I. Frich J, et al. Among authors: lundin ke. Tidsskr Nor Laegeforen. 2014 Jan 14;134(1):14-5. doi: 10.4045/tidsskr.13.1338. Tidsskr Nor Laegeforen. 2014. PMID: 24429749 Free article. Norwegian. No abstract available.
305 results